Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463118 | 0.87 | ADRA2C (0.43) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL282852 | 0.86 | GAA (0.38) | GAAALDH1A1L3MBTL1EGFR | |
| SCHEMBL2033939 | 0.85 | ALDH1A1 (0.46) | MAPTKDM4EGAAPTK2BMAPK1 | |
| SCHEMBL606331 | 0.85 | ALDH1A1 (0.41) | GAAALDH1A1L3MBTL1 | |
| SCHEMBL14940417 | 0.83 | ALDH1A3 (0.45) | MAPTGAAPTK2BMAPK1HTT | |
| SCHEMBL4113163 | 0.81 | DRD2 (0.51) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL1811539 | 0.81 | ADRB1 (0.32) | MAPTGAAPTK2BHTTALDH1A1 | |
| SCHEMBL1811536 | 0.81 | MEN1 (0.36) | MAPTKDM4EGAAPTK2BALDH1A1 | |
| SCHEMBL282584 | 0.81 | KDM4E (0.41) | DRD2MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL16462683 | 0.81 | GAA (0.53) | DRD2DRD3MAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | claimed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| US-9546163-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| JP-4812763-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | claimed |
| US-7868013-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | claimed |
| US-7754714-B2 | (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | claimed |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | claimed |
| EP-1763514-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | claimed |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | claimed |
| WO-2005118544-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| CN-107250116-B | 3, 5-diaminopyrazole kinase inhibitors | 艾士盟医疗公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3237407-B1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | SMA THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-1763514-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| WO-2005118544-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ADRA2C 3804/4885DRD2 3189/4885DRD3 3906/4885 |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | ADRA2C 1873/4885DRD2 4797/4885DRD3 4618/4885 |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | ADRA2C 1873/4885DRD2 4797/4885DRD3 4618/4885 |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ADRA2C 3804/4885DRD2 3189/4885DRD3 3906/4885 |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ADRA2C 3804/4885DRD2 3189/4885DRD3 3906/4885 |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MKI67, PCNA, TK1 | ADRA2C 3804/4885DRD2 3189/4885DRD3 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.